MERTK and leukemia: Given that LAMs express the prototypic efferocytic receptor MerTK, we sought to evaluate whether targeting MerTK-dependent efferocytosis by LAMs would diminish leukemia growth through skewing of the leukemia microenvironment using a novel clinical grade small molecule tyrosine kinase, MRX2843.